Last reviewed · How we verify
STK-012
At a glance
| Generic name | STK-012 |
|---|---|
| Sponsor | Synthekine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STK-012 CI brief — competitive landscape report
- STK-012 updates RSS · CI watch RSS
- Synthekine portfolio CI